Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: RCKT) | Delayed: 2.26 -0.05 (2.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.31 | 52 Week High | $ | |||
| Open | $2.27 | 52 Week Low | $ | |||
| Day High | $2.28 | P/E | N/A | |||
| Day Low | $2.17 | EPS | $ | |||
| Volume | 1,190,739 | |||||
